Denosumab Uses, Dosage, How to Take, Side Effects and Precautions

What is Denosumab? Denosumab (names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone. Denosumab is also used to increase bone mass in women and men with a high risk of bone fracture caused by receiving treatments for certain types of cancer.

Denosumab dosing information:

  • Usual adult dose for osteoporosis: Prolia(R): 60 mg subcutaneously once every 6 months
  • Usual adult dose for giant cell tumor of bone: Xgeva (R): 120 mg subcutaneously every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy
  • Usual adult dose for osteolytic bone metastases of solid tumors: Xgeva(R): 120 mg subcutaneously every 4 weeks
  • Usual adult dose for hypercalcemia of malignancy: Xgeva(R): 120 mg subcutaneously every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy
  • Usual pediatric dose for giant cell tumor of bone: Xgeva (R): 120 mg subcutaneously every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy